Literature DB >> 8053155

Cell tropism of influenza virus mediated by hemagglutinin activation at the stage of virus entry.

R Boycott1, H D Klenk, M Ohuchi.   

Abstract

When influenza virus A/WSN/33 (H1N1) was grown in MDBK or CV-1 cells in serum-free medium, progeny virus released from these cells contained only uncleaved hemagglutinin (HA). This virus was unable to infect CV-1 cells unless subjected to cleavage activation by trypsin, but it was infectious for MDBK cells without such treatment. Temperature shift experiments demonstrated that HA of radiolabeled input virus was cleaved within 30 min after inoculation of MDBK cells. As indicated by its resistance to trypsin cleavage, the virus was already internalized at this stage. Cleavage was not observed after inoculation of CV-1 cells. The serine-protease inhibitor leupeptin blocked virus growth when added to MDBK cells during the initial phase of the replication cycle. The inhibitor did not show this effect, when the input virus contained already cleaved HA. These results demonstrate that activation of HA of the WSN strain can occur in MDBK cells, but not in CV-1 cells, at the stage of virus entry, presumably by an endosomal protease.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8053155     DOI: 10.1006/viro.1994.1489

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  20 in total

1.  Furin is involved in baculovirus envelope fusion protein activation.

Authors:  Marcel Westenberg; Hualin Wang; Wilfred F J IJkel; Rob W Goldbach; Just M Vlak; Douwe Zuidema
Journal:  J Virol       Date:  2002-01       Impact factor: 5.103

2.  Characterization of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) spike glycoprotein-mediated viral entry.

Authors:  Graham Simmons; Jacqueline D Reeves; Andrew J Rennekamp; Sean M Amberg; Andrew J Piefer; Paul Bates
Journal:  Proc Natl Acad Sci U S A       Date:  2004-03-09       Impact factor: 11.205

3.  Proteolytic activation of influenza viruses by serine proteases TMPRSS2 and HAT from human airway epithelium.

Authors:  Eva Böttcher; Tatyana Matrosovich; Michaela Beyerle; Hans-Dieter Klenk; Wolfgang Garten; Mikhail Matrosovich
Journal:  J Virol       Date:  2006-10       Impact factor: 5.103

4.  Proteolytic activation of the 1918 influenza virus hemagglutinin.

Authors:  Chawaree Chaipan; Darwyn Kobasa; Stephanie Bertram; Ilona Glowacka; Imke Steffen; Theodros Solomon Tsegaye; Makoto Takeda; Thomas H Bugge; Semi Kim; Youngwoo Park; Andrea Marzi; Stefan Pöhlmann
Journal:  J Virol       Date:  2009-01-21       Impact factor: 5.103

5.  Evaluation of anti-influenza effects of camostat in mice infected with non-adapted human influenza viruses.

Authors:  M G Lee; K H Kim; K Y Park; J S Kim
Journal:  Arch Virol       Date:  1996       Impact factor: 2.574

6.  Inhibitors of cathepsin L prevent severe acute respiratory syndrome coronavirus entry.

Authors:  Graham Simmons; Dhaval N Gosalia; Andrew J Rennekamp; Jacqueline D Reeves; Scott L Diamond; Paul Bates
Journal:  Proc Natl Acad Sci U S A       Date:  2005-08-04       Impact factor: 11.205

7.  Cell culture as a substrate for the production of influenza vaccines: memorandum from a WHO meeting.

Authors: 
Journal:  Bull World Health Organ       Date:  1995       Impact factor: 9.408

8.  Cleavage of influenza a virus hemagglutinin in human respiratory epithelium is cell associated and sensitive to exogenous antiproteases.

Authors:  Oleg P Zhirnov; Mine R Ikizler; Peter F Wright
Journal:  J Virol       Date:  2002-09       Impact factor: 5.103

9.  A novel mechanism for the acquisition of virulence by a human influenza A virus.

Authors:  H Goto; Y Kawaoka
Journal:  Proc Natl Acad Sci U S A       Date:  1998-08-18       Impact factor: 11.205

10.  Inhibition of influenza A virus replication by compounds interfering with the fusogenic function of the viral hemagglutinin.

Authors:  S J Plotch; B O'Hara; J Morin; O Palant; J LaRocque; J D Bloom; S A Lang; M J DiGrandi; M Bradley; R Nilakantan; Y Gluzman
Journal:  J Virol       Date:  1999-01       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.